Comparison of the efficacy of entecavir and tenofovir in reducing hepatocellular carcinoma risk in chronic hepatitis B patients: a real-life study in Turkey

Basit Öğe Kaydı
dc.authoridKamil Özdil / 0000-0003-2556-3064
dc.authorscopusidKamil Özdil / 23493727900
dc.authorwosidKamil Özdil / JIA-3394-2023
dc.contributor.authorGüzelbulut, Fatih
dc.contributor.authorGökçen, Pınar
dc.contributor.authorCan, Güray
dc.contributor.authorAdalı, Gupse
dc.contributor.authorSaltürk, Ayça Gökçen Değirmenci
dc.contributor.authorAslan, Ekrem
dc.contributor.authorÖzdil, Kamil
dc.contributor.authorDoganay, Hamdi Levent
dc.date.accessioned2021-07-28T05:27:00Z
dc.date.available2021-07-28T05:27:00Z
dc.date.issued2021en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractBackground: It is controversial whether entecavir or tenofovir differs in reducing hepatocellular carcinoma (HCC) risk. We aimed to compare the efficacy of entecavir and tenofovir in reducing HCC risk in chronic hepatitis B (CHB) patients. Methods: This retrospective study included 607 nucleos(t)ide naive CHB patients who had received entecavir or tenofovir. Patients who developed HCC during the first 12 months of therapy were excluded. Cumulative HCC incidences at years 2, 3, 4, 5 and 10 were compared between entecavir and tenofovir groups. Factors associated with HCC were determined by univariate and multivariate analyses. Results: Nineteen (3.1%) patients developed HCC, 12 (4.8%) in entecavir group and 7 (1.9%) in tenofovir group (P = .045). In the entire cohort, cumulative HCC incidences at years Z 3, 4, 5 and 10 were 1.8%, 2.9%, 4.4%, 5.2% and 9.9% in entecavir group, and 0.6%, 2.4%, 2.4%, 2.4% and 3.7% in tenofovir group, respectively (log-rank P = .130). In multivariate analysis, age >= 50 years, cirrhosis, decompensated cirrhosis, high GGT and low platelet levels were associated with HCC in the entire cohort. In advanced fibrosis/cirrhosis cohort, cumulative HCC incidences at years 2, 3, 4, 5 and 10 were 4.6%, 7.1%, 8.6%,12.1% and 15.5% in entecavir group, and 1.8%, 5.6%, 5.6%, 5.6% and 8.5% in tenofovir group, respectively (log-rank P = .267). In multivariate analysis, age >= 50 years, decompensated cirrhosis, high GOT and low platelet levels were associated with HCC in the advanced fibrosis/cirrhosis cohort. Conclusion: Entecavir and tenofovir are similarly effective in reducing HCC risk in CHB patients.en_US
dc.identifier.citationGüzelbulut, F., Gökçen, P., Can, G., Adalı, G., Saltürk, A. G. D., Aslan, E., ... & Doğanay, H. L. (2021). Comparison of the Efficacy of Entecavir and Tenofovir in Reducing Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients: A Real-Life Study in Turkey. Turk J Gastroenterol, 32(4), 412-421.en_US
dc.identifier.doi10.5152/tjg.2021.20423en_US
dc.identifier.endpage421en_US
dc.identifier.issn2148-5607en_US
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-85109446529en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage412en_US
dc.identifier.urihttps://doi.org/10.5152/tjg.2021.20423
dc.identifier.urihttps://hdl.handle.net/20.500.12713/1948
dc.identifier.volume32en_US
dc.identifier.wosWOS:000670759200009en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorÖzdil, Kamil
dc.language.isoenen_US
dc.publisherAVESen_US
dc.relation.ispartofTURKISH JOURNAL OF GASTROENTEROLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleComparison of the efficacy of entecavir and tenofovir in reducing hepatocellular carcinoma risk in chronic hepatitis B patients: a real-life study in Turkeyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
105.pdf
Boyut:
1.77 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
İSÜ Hastaneleri Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu